Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.

Diabetes Technology & Therapeutics
Robert R HenryArie Katz

Abstract

Glycated hemoglobin (HbA1c) and measures of short-term glycemia do not fully capture daily patterns in plasma glucose dynamics. This study evaluated 24-h glycemic profiles in patients with type 2 diabetes (T2D) initiated on dapagliflozin treatment using continuous glucose monitoring (CGM). This randomized double-blind placebo-controlled multicenter parallel-design 4-week study compared dapagliflozin (10 mg/d; n = 50) with placebo (n = 50) in adult patients with T2D uncontrolled (HbA1c 7.5%-10.5%) on either stable doses of metformin monotherapy (≥1500 mg/d) or insulin (≥30 U/d with or without up to two oral antidiabetes drugs). CGM was used to measure 24-h glycemic profiles for 7 days pretreatment and during week 4 of treatment. The primary outcome was change from baseline in 24-h mean glucose (MG) at week 4. The 24-h MG decreased 18.2 mg/dL with dapagliflozin and increased 5.8 mg/dL with placebo (P < 0.001). The proportion of time spent in the target glucose range (70-180 mg/dL) increased significantly with dapagliflozin versus placebo (69.6% vs. 52.9%; P < 0.001), with a small (0.3%) increase in time spent in the hypoglycemic range (<70 mg/dL), driven by those on background insulin therapy. Dapagliflozin reduced postprandial g...Continue Reading

References

Apr 13, 2006·JAMA : the Journal of the American Medical Association·Louis MonnierClaude Colette
Feb 15, 2008·Diabetes Care·Louis Monnier, Claude Colette
Feb 5, 2011·Diabetes Technology & Therapeutics·Gert FritzscheEckhard Salzsieder
Sep 2, 2011·Journal of Diabetes Science and Technology·Cynthia R MarlingFrank L Schwartz
Mar 21, 2012·Annals of Internal Medicine·John P H WildingUNKNOWN Dapagliflozin 006 Study Group
Dec 3, 2014·International Journal of Clinical Practice·S ParikhE Hardy
Feb 11, 2015·Diabetic Medicine : a Journal of the British Diabetic Association·J P NewG Freckmann
Dec 24, 2015·Diabetes Care·UNKNOWN American Diabetes Association
May 22, 2016·Diabetes Care·Boris Kovatchev, Claudio Cobelli

❮ Previous
Next ❯

Citations

May 1, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Haleh ChehregoshaFaramarz Ismail-Beigi
Feb 21, 2019·Diabetes Technology & Therapeutics·Satish K Garg
Dec 24, 2018·Diabetes Technology & Therapeutics·Robert A Vigersky, Chantal McMahon
Feb 19, 2020·Diabetes Technology & Therapeutics·Satish K GargIrl B Hirsch
Jul 6, 2020·Cardiovascular Diabetology·Zheng ZhouMeng Bian
Oct 28, 2020·Diabetes Technology & Therapeutics·David Rodbard
Nov 30, 2019·Diabetes Research and Clinical Practice·Paul Valensi, Gaëtan Prévost
Aug 28, 2021·Antioxidants·Tatsuya Maruhashi, Yukihito Higashi
Sep 28, 2021·Frontiers in Endocrinology·Anne-Esther BreytonJulie-Anne Nazare
Jul 17, 2021·Diabetes Technology & Therapeutics·Bruce BodeDebra Ignaut
Jun 14, 2021·Diabetes Research and Clinical Practice·Hideaki JinnouchiTomio Jinnouchi
Nov 3, 2020·Clinical Diabetes : a Publication of the American Diabetes Association·Pamela R Kushner, Davida F Kruger

❮ Previous
Next ❯

Methods Mentioned

BETA
blood draws

Clinical Trials Mentioned

NCT02429258

Software Mentioned

Interactive Web Response System
Interactive Voice Response System

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.